Heimat x WIIID – THC Online Shop Switzerland (Pilot Project)
With WIIID, Heimat is taking a pioneering step into the future of regulated cannabis in Switzerland. Together with the University of Bern, the University of Zurich, the Cantonal Police, the Federal Office of Public Health (BAG), and other partners, a federally authorised pilot project is underway — exploring the legal sale of THC products in Switzerland.
As part of WIIID, the controlled sale of recreational cannabis is being scientifically evaluated. The project includes Switzerland’s first official nationwide online shop for THC products — operated under strict regulatory oversight and accessible exclusively to a registered research cohort.
Heimat contributes to this initiative through a brand partnership with ESSENCE VERT GmbH, the company developing and operating the platform.
Through WIIID, we gain access to real-world market data, direct consumer insights, and scientific evidence to help shape the future regulation of cannabis in Switzerland. All under the close supervision of public health authorities and scientific partners.
For Heimat, this means: a pioneering role, a head start, and a clear knowledge advantage.
WIIID aims to build a future where recreational cannabis use is informed, transparent, and socially responsible — addressing critical issues such as consumer protection, industry transparency, prevention, and the scientific understanding of cannabis.
Heimat Manufaktur AG is proud to play a central role in this!
Cannabis & Science: Clinical Insights
Modern medicine is increasingly recognising the role of plant-based compounds in holistic patient care. In particular, cannabidiol (CBD) has gained attention for its potential calming, anti-inflammatory and anxiolytic properties. A growing number of clinical studies and observational trials suggest that cannabinoids may play a supportive role in areas such as psychiatry, oncology, neurology and internal medicine.
These applications are not positioned as replacements for conventional treatments, but as complementary interventions within an evidence-based medical context.
A growing number of clinical studies suggest that cannabinoids may play a supportive role across a range of fields, including pain management, oncology, rheumatology, sleep medicine, and mental health. Examples include:
Clinical studies with Heimat products
Heimat Manufaktur AG has supported several Swiss clinical pilot projects by providing its functional cannabis products – including Cannabis teas, hemp flowers and pre-rolls (tobacco-free hemp cigarettes) – in several clinical studies in Swiss clinics and universities.
The products used are made from 100% Swiss grown hemp and are free from artificial additives, tobacco and nicotine. They contain less than 1% THC and are therefore not psychoactive – a decisive advantage for everyday clinical use.
We believe in sharing data, not overclaiming.
Therapeutic Applications CBD
CBD-based formulations developed by Heimat are designed for use in both humans and animals, in alignment with a natural, plant-based approach to wellbeing. Customers incorporate them into routines aimed at supporting chronic discomfort, neurological balance, restful sleep, and overall calm.
Our approach to product development follows scientific research and prioritises tolerability and safety – read more under Research & Development.
We closely monitor ongoing research into the role of cannabinoids in clinical contexts such as pain management, neurology, and behavioural health, and adapt our product development accordingly.
Pharmacies & Medical Professionals
Heimat collaborates with pharmacies, physicians, and clinics across Switzerland, and is actively preparing for a structured expansion into medical cannabis care across the DACH region. We support healthcare professionals through continuing education, research partnerships, and access to standardised product documentation — fostering trust and confidence in cannabinoid-based care.
Want to partner with us? Let's talk!
